Analysis of prognostic factors in patients with advanced non-small cell lung cancer (NSCLC) who are candidates to receive a second-line treatment

被引：2
|
作者：
Provencio, M.
Cobo, M.
Vazquez-Estevez, S.
Firvida, J.
Macia, S.
Barneto, I.
Oramas, J.
Sanchez-Hernandez, A.
Ferrer, N.
Paredes, A.
机构：
[1] Hosp Puerta de Hierro, Madrid, Spain
[2] Hosp Univ Carlos Haya, Malaga, Spain
[3] Complexo Xeral Calde, Lugo, Spain
[4] Complexo Hosp Ourense, Orense, Spain
[5] Hosp Gen Elda, Elda, Spain
[6] Hosp Univ Reina Sofia, Dept Clin Oncol, Cordoba, Spain
[7] Hosp Univ Canarias, Santa Cruz De Tenerife, Spain
[8] Hosp Prov Castellon, Castellon de La Plana, Spain
[9] Hosp Son Llatzer, Palma De Mallorca, Spain
[10] Hosp Donostia, San Sebastian, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e18109
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18109
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Future directions in the second-line treatment of non-small cell lung cancer
    Rosell, R
    Cecere, F
    Cognetti, F
    Cuello, M
    Sanchez, JM
    Taron, M
    Reguart, N
    Jablons, D
    SEMINARS IN ONCOLOGY, 2006, 33 (01) : S45 - S51
  • [42] Second-line chemotherapy for non-small cell lung cancer
    De Marinis, F.
    De Santis, S.
    De Petris, L.
    ANNALS OF ONCOLOGY, 2006, 17 : V68 - V71
  • [43] Non-small cell lung cancer: second-line and beyond
    Stahel, R. A.
    ANNALS OF ONCOLOGY, 2006, 17 : X97 - X100
  • [44] Second-line chemotherapy for non-small cell lung cancer
    Ruckdeschel, JC
    CHEST, 2006, 129 (04) : 840 - 842
  • [45] From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?
    Ettore D’Argento
    Sabrina Rossi
    Giovanni Schinzari
    Antonia Strippoli
    Michele Basso
    Alessandra Cassano
    Carlo Barone
    Current Treatment Options in Oncology, 2016, 17
  • [46] Influence of Radiotherapy in Second-Line Treatment with Immunotherapy in Patients with Non-Small Cell Lung Cancer
    Azkona, E.
    Carrera, S.
    Rubio, I.
    Mane, J. M.
    Lacambra, I.
    Sancho, A.
    Novo, E.
    Lopez-Vivanco, G.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S969 - S969
  • [47] Toripalimab combined with chemotherapy as second-line treatment of advanced non-small cell lung cancer (NSCLC): A single center retrospective study
    Jiang, M.
    Wang, Y.
    Zhang, X.
    ANNALS OF ONCOLOGY, 2021, 32 : S1010 - S1010
  • [48] Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer
    Reckamp, Karen L.
    CANCER LETTERS, 2012, 321 (02) : 101 - 109
  • [49] Gemcitabine in the first and second-line chemotherapy of advanced non-small cell lung cancer
    Cucevic, B
    Samarzija, M
    Baricevic, D
    Jakopovic, M
    Redzepi, G
    Samija, M
    COLLEGIUM ANTROPOLOGICUM, 2005, 29 (02) : 583 - 588
  • [50] The Role of Pemetrexed in Second-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer
    Tucker, Steven
    CURRENT DRUG TARGETS, 2010, 11 (01) : 58 - 60
12345